submit to the journals

Surgery and Neurointervention for Intracranial Atherosclerotic Steno-occlusive Disease

European Neurological Review, 2013;8(2):170–4 DOI: http://doi.org/10.17925/ENR.2013.08.02.170

Abstract:

Neurosurgeons and neurointerventionists interested in cerebral revascularisation to prevent stroke from intracranial atherosclerotic steno-occlusive disease were disappointed in 2011 with the closure of two important negative studies: the Carotid Occlusion Surgery Study (COSS) and Stenting and Aggressive Medical Therapy for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) study. Debates are centred on what causes these failures. While extracranial-intracranial (EC-IC) bypass and neurointervention (angioplasty and/ or stenting) cannot be considered a routine intervention for patients presenting with initial ischaemic event in the setting of atherosclerotic steno-occlusive disease, selected patients with severe haemodynamic impairment and/or recurrent symptoms despite maximal medical therapy may still benefit from surgery and neurointervention at high-volume centres, which can offer the procedure with low perioperative morbidity.
Keywords: Angioplasty, cerebral ischaemia, EC-IC bypass, stenting, stroke
Disclosure: The authors have no conflicts of interest to declare.
Received: August 05, 2013 Accepted: October 31, 2013
Correspondence: George Kwok-Chu Wong, Professor (Clinical), Division of Neurosurgery, Department of Surgery, 4/F Clinical Science Building, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR China. E: georgewong@surgery.cuhk.edu.hk
An erratum to this article can be found below.

Surgery for Occlusive Atherosclerotic Disease
Extracranial-intracranial (EC-IC) bypass for revascularisation in the setting of atherosclerotic occlusive disease has remained a topic of intense interest and scrutiny over the last four decades. The underlying premise of EC-IC bypass in this setting is to provide blood flow augmentation in the setting of cerebral ischaemia, aiming to improve blood flow to oligemic brain tissue.

Evidence for Extracranial-Intracranial Bypass
Anterior Circulation
In evaluating the efficacy of EC-IC bypass for ischaemia, the primary focus has been on anterior circulation disease. Flow augmentation bypass in the anterior circulation primarily entails a bypass between the superficial temporal artery and the middle cerebral artery (STA-MCA). The EC-IC bypass study published in 1985 failed to demonstrate the efficacy of STA-MCA bypass over medical management in over 1,300 patients with occlusive disease of the anterior circulation.1 Patients with transient ischaemic attack (TIA) or stroke in the setting of occlusive disease not amenable to carotid endarterectomy (primarily carotid occlusion) were randomised to best medical therapy or best medical therapy in addition to EC-IC bypass. Although surgery was performed successfully, with a reported bypass patency rate of 96 %, EC-IC bypass conferred no benefit in terms of stroke risk over the average follow-up period of 55.8 months.

Subsequent analysis of the study methodology identified shortcomings in study design and implementation that suggested universal abandonment of EC-IC bypass for ischaemic was premature.2,3 The trial was criticised for potential selection bias in enrolment, with concerns that a large number of patients, more than enrolled within the study, actually underwent surgery outside the trial. This would suggest that patients may have been selectively offered surgery versus enrolment in the trial based on perceived benefit of intervention, thus diluting any beneficial effect of bypass in those within the study cohort. Concern was also raised regarding the adequacy of flow augmentation provided by the STA-MCA bypass, with the notion that higher flows through larger calibre bypass could be more effective. The STA-MCA bypass has been the primary type of bypass performed in the setting of ischaemia, due to its high technical success rate and low morbidity given that anastomosis is performed to a distal cortical MCA branch with little risk of ischaemia during crossclamping. 4 However, the degree of flow augmentation can be relatively modest compared with larger conduit bypasses such as vein or radial artery interposition grafts from the cervical carotid to the more proximal MCA. Larger conduits do carry several disadvantages, however, including higher morbidity and lower patency rates,5 and the risk of ischaemia during cross-clamping of the more proximal MCA. Additionally, there is concern for hyperperfusion haemorrhage when using high flow grafts to revascularise ischaemic brain,6 presumed to be due to the inability of the vasodilated ischaemic vascular bed to compensate acutely to a large increase in perfusion created by a high flow graft. Favourable preliminary results with higher flow grafts in small series have been reported with the use of a non-occlusive bypass technique, the excimer laser-assisted anastomosis (ELANA), which allows vein grafts to be placed onto large proximal vessels, such as the supraclinoid carotid artery or proximal MCA, without clamping the vessel during anastomosis.7,8 This technique is still under evaluation, but the lack of temporary vessel occlusion during surgery, or the more physiological placement of the bypass proximally in the intracranial circulation, appears to reduce the risk of hyperperfusion.7

The most prominent drawback of the EC-IC bypass trial, which ultimately generated the most subsequent analysis and investigation, was the lack of haemodynamic evaluation in selecting patients for enrolment. In the trial, no objective physiological criteria were used to assess cerebral blood flow, and thus patients may have presented with ischaemic symptoms secondary to aetiologies unlikely to benefit from bypass, such as embolic phenomena or small vessel disease. Subsequent to the ECIC bypass trial, the role of haemodynamic assessment in evaluation of carotid occlusive disease has been extensively evaluated, demonstrating that haemodynamic evaluation can identify a subgroup at higher risk of recurrent stroke,9–15 and who would, therefore, be more appropriate candidates for revascularisation. In the last two decades, two trials have attempted to address the efficacy of bypass in such patients with haemodynamic compromise. The Japanese EC-IC bypass trial (JET) randomised patients with symptomatic internal carotid artery (ICA) or MCA occlusive and haemodynamic impairment to undergo STA-MCA bypass versus medical therapy. Interim results based on analysis of 196 patients published in a Japanese language journal reported a favourable result for bypass at two-year follow-up,16 with a reduced risk of the primary endpoint of death and stroke (23.1 % in the medical arm and 15.2 % in the surgical arm; p=0.046). The Carotid Occlusion Surgery Study (COSS) based in the US, however, did not support the efficacy of bypass for stroke-risk reduction.17

References:
  1. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group, N Engl J Med, 1985;313:1191–200.
  2. Sundt TM, Jr, Was the international randomized trial of extracranial-intracranial arterial bypass representative of the population at risk?, N Engl J Med, 1987;316:814–6.
  3. Goldring S, Zervas N, Langfitt T, The Extracranial-Intracranial Bypass Study. A report of the committee appointed by the American Association of Neurological Surgeons to examine the study, N Engl J Med, 1987;316:817–20.
  4. Horn P, Scharf J, Pena-Tapia P, Vajkoczy P, Risk of intraoperative ischemia due to temporary vessel occlusion during standard extracranial-intracranial arterial bypass surgery, J Neurosurg, 2008;108:464–9.
  5. Regli L, Piepgras DG, Hansen KK, Late patency of long saphenous vein bypass grafts to the anterior and posterior cerebral circulation, J Neurosurg, 1995;83:806–11.
  6. Stiver SI, Ogilvy CS, Acute hyperperfusion syndrome complicating EC-IC bypass, J Neurol Neurosurg Psychiatry, 2002;73:88–9.
  7. Langer DJ, Van Der Zwan A, Vajkoczy P, et al., Excimer laserassisted nonocclusive anastomosis. An emerging technology for use in the creation of intracranial-intracranial and extracranialintracranial cerebral bypass, Neurosurg Focus, 2008;24:E6.
  8. Klijn CJ, Kappelle LJ, van der Zwan A, et al., Excimer laserassisted high-flow extracranial/intracranial bypass in patients with symptomatic carotid artery occlusion at high risk of recurrent cerebral ischemia: safety and long-term outcome, Stroke, 2002;33:2451–8.
  9. Kleiser B, Widder B, Course of carotid artery occlusions with impaired cerebrovascular reactivity, Stroke, 1992;23:171–4.
  10. Kuroda S, Houkin K, Kamiyama H, et al., Long-term prognosis of medically treated patients with internal carotid or middle cerebral artery occlusion: can acetazolamide test predict it?, Stroke, 2001;32:2110–16.
  11. Ogasawara K, Ogawa A, Yoshimoto T, Cerebrovascular reactivity to acetazolamide and outcome in patients with symptomatic internal carotid or middle cerebral artery occlusion: a xenon-133 single-photon emission computed tomography study, Stroke, 2002;33:1857–62.
  12. Vernieri F, Pasqualetti P, Passarelli F, et al., Outcome of carotid artery occlusion is predicted by cerebrovascular reactivity, Stroke, 1999;30:593–8.
  13. Webster MW, Makaroun MS, Steed DL, et al., Compromised cerebral blood flow reactivity is a predictor of stroke in patients with symptomatic carotid artery occlusive disease, J Vasc Surg, 1995;21:338–44.
  14. Grubb RL Jr, Derdeyn CP, Fritsch SM, et al., Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion, JAMA, 1998;280:1055–60.
  15. Yamauchi H, Fukuyama H, Nagahama Y, et al., Significance of increased oxygen extraction fraction in five-year prognosis of major cerebral arterial occlusive diseases, J Nucl Med, 1999;40:1992–8.
  16. Ogasawara K, Ogawa A, [JET study (Japanese EC-IC Bypass Trial)], Nippon Rinsho, 2006;64(Suppl. 7):524–7.
  17. Powers WJ, Clarke WR, Grubb RL Jr, et al., Extracranialintracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial, JAMA, 2011;306:1983–92.
  18. Grubb RL Jr, Powers WJ, Derdeyn CP, et al., The carotid occlusion surgery study, Neurosurg Focus, 2003;14:e9.
  19. Derdeyn CP, Gage BF, Grubb RL, Jr, Powers WJ, Cost-effectiveness analysis of therapy for symptomatic carotid occlusion: PET screening before selective extracranial-to-intracranial bypass versus medical treatment, J Nucl Med, 2000;41:800–807.
  20. Amin-Hanjani S, Barker FG, 2nd, Charbel FT, et al., Extracranialintracranial bypass for stroke-is this the end of the line or a bump in the road?, Neurosurgery, 2012;71:557–61. 21. Chimowitz MI, Lynn MJ, Derdeyn CP, et al., Stenting versus aggressive medical therapy for intracranial arterial stenosis, N Engl J Med, 2011;365:993–1003.
  21. Amarenco P, Benavente O, Goldstein LB, et al., Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes, Stroke, 2009;40:1405–9.
  22. Carlson AP, Yonas H, Chang YF, Nemoto EM, Failure of cerebral hemodynamic selection in general or of specific positron emission tomography methodology?: Carotid Occlusion Surgery Study (COSS), Stroke, 2011;42:3637–9.
  23. Grubb RL, Jr, Powers WJ, Clarke WR, et al., Surgical results of the Carotid Occlusion Surgery Study, J Neurosurg, 2013;118:25–33.
  24. Fiedler J, Priban V, Skoda O, et al., Cognitive outcome after EC-IC bypass surgery in hemodynamic cerebral ischemia, Acta Neurochir (Wien), 2011;153:1303–11; discussion 1311–12.
  25. Sasoh M, Ogasawara K, Kuroda K, et al., Effects of EC-IC bypass surgery on cognitive impairment in patients with hemodynamic cerebral ischemia, Surg Neurol, 2003;59:455–60.
  26. Horn P, Scharf J, Pena-Tapia P, Vajkoczy P, Risk of intraoperative ischemia due to temporary vessel occlusion during standard extracranial-intracranial arterial bypass surgery, J Neurosurg, 2008;108:464–9.
  27. Fierstra J, Maclean DB, Fisher JA, et al., Surgical revascularization reverses cerebral cortical thinning in patients with severe cerebrovascular steno-occlusive disease, Stroke, 2011;42:1631–7.
  28. Inoue T, Jinnouchi J, Changes in brain volume after EC-IC bypass surgery, Acta Neurochir Suppl, 2008;103:79–82.
  29. Ogasawara K, Komoribayashi N, Kobayashi M, et al., Neural damage caused by cerebral hyperperfusion after arterial bypass surgery in a patient with moyamoya disease: case report, Neurosurgery, 2005;56:E1380.
  30. Nakagawa A, Fujimura M, Arafune T, et al., Clinical implications of intraoperative infrared brain surface monitoring during superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease, J Neurosurg, 2009;111:1158–64
  31. Hopkins LN, Budny JL, Complications of intracranial bypass for vertebrobasilar insufficiency, J Neurosurg, 1989;70:207–11.
  32. Ausman JI, Diaz FG, Vacca DF, Sadasivan B, Superficial temporal and occipital artery bypass pedicles to superior, anterior inferior, and posterior inferior cerebellar arteries for vertebrobasilar insufficiency, J Neurosurg, 1990;72:554–8.
  33. Haase J, Magnussen IB, Ogilvy CS, et al., Evaluating patients with vertebrobasilar transient ischemic attacks, Surg Neurol, 1999;52:386–92.
  34. Amin-Hanjani S, Du X, Zhao M, et al., Use of quantitative magnetic resonance angiography to stratify stroke risk in symptomatic vertebrobasilar disease, Stroke, 2005;36:1140–45.
  35. Amin-Hanjani S, Rose-Finnell L, Richardson D, et al., Vertebrobasilar Flow Evaluation and Risk of Transient Ischaemic Attack and Stroke study (VERiTAS): rationale and design, Int J Stroke, 2010;5:499–505.
  36. Tummala RP, Chu RM, Nussbaum ES, Extracranial-intracranial bypass for symptomatic occlusive cerebrovascular disease not amenable to carotid endarterectomy, Neurosurg Focus, 2003;14:e8.
  37. Amin-Hanjani S, Charbel FT, Is extracranial-intracranial bypass surgery effective in certain patients?, Neurosurg Clin N Am, 2008;19:477–87.
  38. Sacco RL, Kargman DE, Gu Q, et al., Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction, Stroke, 1995;26:14–20.
  39. Broderick J, Brott T, Kothari R, et al., The Greater Cincinnati/ Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks, Stroke, 1998;29:415–21.
  40. Wong KS, Huang YN, Gao S, et al., Intracranial stenosis in Chinese patients with acute stroke, Neurology, 1998;50:812–13. 42. Bogousslavsky J, Barnett HJ, Fox AJ, et al., Atherosclerotic disease of the middle cerebral artery, Stroke, 1986;17:1112–20.
  41. Chimowitz MI, Kokkinos J, Strong J, et al., The Warfarin- Aspirin symptomatic intracranial disease study, Neurology, 1995;45:1488–93.
  42. Thijs VN, Albers GW, Symptomatic intracranial atherosclerosis: Outcome of patients who fail antithrombotic therapy, Neurology, 2000;55:490–97.
  43. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al., Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis, N Engl J Med, 2005;352:1305–16.
  44. The EC/IC Bypass Study Group, Failure of extracranialintracranial arterial bypass to reduce the risk of ischemic stroke (results of an international randomized trial), N Engl J Med, 1985;313:1191–200.
  45. Rundek T, Elkind MS, Chen X, Increased early stroke recurrence among patients with extracranial and intracranial atherosclerosis: Northern Manhattan Stroke Study, Neurology, 1998;50(Suppl. 4):A75.
  46. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Prognosis of patients with symptomatic vertebral or basilar artery stenosis, Stroke, 1998;29:1389–92.
  47. Caplan LR, Advances in stroke research: Basic science, treatment, and clinical trial outcomes, Rev Neurol Dis, 2004;2:91–4.
  48. Qureshi AI, Feldmann E, Gomez CR, et al., Consensus conference on intracranial atherosclerotic disease: rationale, methodology, and results, J Neuroimaging, 2009;19:1S–10S.
  49. Bose A, Hartmann M, Henkes H, et al., A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study, Stroke, 2007;38:1531–7.
  50. Fiorella D, Levy EI, Turk AS, et al., US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results, Stroke, 2007;38:881–7.
  51. Zaidat OO, Klucznik R, Alexander MJ, et al., NIH Multi-center Wingspan Intracranial Stent Registry Study Group. The NIH registry on use of the Wingspan stent for symptomatic 70–99 % intracranial arterial stenosis, Neurology, 2008;70:1518–24.
  52. Albuquerque FC, Levy EI, Turk AS, et al., Angiographic patterns of Wingspan in-stent restenosis, Neurosurgery, 2008;63:23–7.
  53. Chimowitz MI, Lynn MJ, Derdeyn CP, et al., Stenting versus Aggressive medical therapy for intracranial arterial stenosis, N Engl J Med, 2011;365:993–1003.
  54. Gray WA, Yadav JS, Verta P, et al., The CAPTURE registry: predictors of outcomes in carotid artery stenting with embolic protection for high surgical risk patients in the early post-approval setting, Catheter Cardiovasc Interv, 2007;70:1025–33.
  55. Topakian R, Strasak AM, Sonnberger M, et al., Timing of stenting of symptomatic carotid stenosis is predictive of 30- day outcome, Eur J Neurol, 2007;14:672–8.
  56. Fiorella D, Derdeyn CP, Lynn MJ, et al., Detailed Analysis of Periprocedural Strokes in Patients Undergoing Intracranial Stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS), Stroke, 2012;43:2682–16888.
  57. Jiang WJ, Yu W, Du B, Gao F, Cui LY, Outcome of patients with ≥70% symptomatic intracranial stenosis after wingspan stenting, Stroke, 2011;42:1971–5.
  58. Jiang WJ, Du B, Leung TW, Xu XT, et al., Symptomatic intracranial stenosis: cerebrovascular complications from elective stent placement, Radiology, 2007;243:188–97.
  59. Yu SC, Leung TW, Hung EH, et al., Angioplasty and stenting for intracranial atherosclerotic stenosis with nitinol stent: factors affecting technical success and patient safety, Neurosurgery, 2012;70(1 Suppl. Operative):104–13.
  60. Yu CH, Leung WH, Hung HY, et al., Angioplasty and stenting of intracranial atherosclerosis with Wingspan system evaluation of factors affecting one-year restenosis of 66 cases in a single center. 97th Scientific Assembly and Annual Meeting of the RSNA 2011, Chicago, USA, 27.
  61. Tomycz L, Bansal NK, Lockney T, et al., Primary balloon angioplasty for symptomatic, high-grade intracranial stenosis, Surg Neurol Int, 2013; 4:18.
  62. Alkukar A, Karanam LS, Oak S, et al., Role of balloonexpandable stents in intracranial atherosclerotic disease in a series of 182 patients, Stroke, 2013;44:2000–2003.
  63. Wong GK, Poon WS, Time to reflect on surgery and neurointervention for intracranial atherosclerotic diseases, J Clin Neurosci, 2012;19:222–3.
Keywords: Angioplasty, cerebral ischaemia, EC-IC bypass, stenting, stroke
pdf icon Errata pdf